Bradmer Pharmaceuticals Inc. (TSE:GLX – Free Report) – Analysts at HC Wainwright decreased their Q1 2026 earnings per share estimates for Bradmer Pharmaceuticals in a research report issued on Wednesday, February 4th. HC Wainwright analyst M. Colonnese now expects that the company will post earnings of ($0.68) per share for the quarter, down from their previous forecast of ($0.11). HC Wainwright also issued estimates for Bradmer Pharmaceuticals’ Q2 2026 earnings at ($0.04) EPS, Q3 2026 earnings at $0.12 EPS, Q4 2026 earnings at $0.16 EPS and FY2026 earnings at ($0.44) EPS.
Separately, Citizens Jmp upgraded Bradmer Pharmaceuticals to a “strong-buy” rating in a research note on Tuesday, December 9th. Six research analysts have rated the stock with a Strong Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Strong Buy”.
Bradmer Pharmaceuticals Price Performance
Featured Stories
- Five stocks we like better than Bradmer Pharmaceuticals
- Your Bank Account Is No Longer Safe
- When to buy gold (mathematically)
- Nervous about the stock market? Read this
- NEW LAW: Congress Approves Setup For Digital Dollar?
- Buffett, Gates and Bezos Quietly Dumping Stocks—Here’s Why
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
